https://orcid.org/0000-0002-9061-3593
Abstract
We used single-cell genomics to characterize a patient with T-cell acute lymphoblastic leukemia treated in the Children’s Oncology Group AALL0434 trial with poor clinical outcome despite favorable genomic features, identifying a STAT1-mediated interferon-related transcriptional signature and inflammatory microenvironment associated with sensitivity to small-molecule JAK inhibition.
References
1.
Wood
BL
, Winter
SS
, Dunsmore
KP
, et al. T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children’s Oncology Group (COG) Study AALL0434 [abstract]
. Blood
. 2014
;124
(21
):1
.2.
Hunger
SP
, Mullighan
CG
. Acute lymphoblastic leukemia in children.
. N Engl J Med
. 2015
;373
(16
):1541
-1552
.3.
Maude
SL
, Dolai
S
, Delgado-Martin
C
, et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia
. Blood
. 2015
;125
(11
):1759
-1767
.4.
Delgado-Martin
C
, Meyer
LK
, Huang
BJ
, et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias
. Leukemia
. 2017
;31
(12
):2568
-2576
.5.
Chen
C
, Xu
J
, Vincent
T
, et al. Treatment Resistance in ETP-ALL is associated with progenitor-like arrest state [abstract]
. Blood
. 2021
;138
(suppl 1
):618
.6.
Weichselbaum
RR
, Ishwaran
H
, Yoon
T
, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer
. Proc Natl Acad Sci U S A
. 2008
;105
(47
):18490
-18495
.7.
Han
H
, Cho
JW
, Lee
S
, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions
. Nucleic Acids Res
. 2018
;46
(D1
):D380
-D386
.8.
Pölönen
P
, Di Giacomo
D
, Seffernick
AE
, et al. The genomic basis of childhood T-lineage acute lymphoblastic leukaemia
. Nature
. 2024
;632
(8027
):1082
-1091
.9.
Waldman
AD
, Fritz
JM
, Lenardo
MJ
. A guide to cancer immunotherapy: from T cell basic science to clinical practice
. Nat Rev Immunol
. 2020
;20
(11
):651
-668
.10.
Pitroda
SP
, Stack
ME
, Liu
GF
, et al. JAK2 inhibitor SAR302503 abrogates PD-L1 expression and targets therapy-resistant non-small cell lung cancers
. Mol Cancer Ther
. 2018
;17
(4
):732
-739
.11.
Benci
JL
, Xu
B
, Qiu
Y
, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade
. Cell
. 2016
;167
(6
):1540
-1554.e12
.12.
Jaramillo
S
, Hennemann
H
, Horak
P
, et al. Ruxolitinib is effective in the treatment of a patient with refractory T-ALL
. EJHaem
. 2021
;2
(1
):139
-142
.13.
Kołodrubiec
J
, Kozłowska
M
, Irga-Jaworska
N
, et al. Efficacy of ruxolitinib in acute lymphoblastic leukemia: a systematic review
. Leuk Res
. 2022
;121
:106925
.14.
Naqvi
K
, Verstovsek
S
, Kantarjian
H
, Ravandi
F
. A potential role of ruxolitinib in leukemia
. Expert Opin Investig Drugs
. 2011
;20
(8
):1159
-1166
.15.
Verbeke
D
, Gielen
O
, Jacobs
K
, et al. Ruxolitinib synergizes with dexamethasone for the treatment of T-cell acute lymphoblastic leukemia
. HemaSphere
. 2019
;3
(6
):e310
.16.
Senkevitch
E
, Li
W
, Hixon
JA
, et al. Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations
. Oncotarget
. 2018
;9
(32
):22605
-22617
.17.
Lan
Q
, Peyvandi
S
, Duffey
N
, et al. Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer
. Oncogene
. 2019
;38
(15
):2814
-2829
.18.
Erdal
E
, Haider
S
, Rehwinkel
J
, Harris
AL
, McHugh
PJ
. A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1
. Genes Dev
. 2017
;31
(4
):353
-369
.19.
Sistigu
A
, Yamazaki
T
, Vacchelli
E
, et al. Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
. Nat Med
. 2014
;20
(11
):1301
-1309
.20.
Meyer
SC
, Keller
MD
, Chiu
S
, et al. CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms
. Cancer Cell
. 2015
;28
(1
):15
-28
.21.
Lee
SHR
, Yang
W
, Gocho
Y
, et al. Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response
. Nat Med
. 2023
;29
(1
):170
-179
.22.
Duarte
CW
, Willey
CD
, Zhi
D
, et al. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner
. PLOS ONE
. 2012
;7
(1
):e29653
.23.
Khodarev
NN
, Roach
P
, Pitroda
SP
, et al. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy
. PLoS ONE
. 2009
;4
(6
):e5821
.24.
Lo
U
, Chen
Y
, Cen
J
, et al. The driver role of JAK-STAT signalling in cancer stemness capabilities leading to new therapeutic strategies for therapy- and castration-resistant prostate cancer
. Clin Transl Med
. 2022
;12
(8
):e978
.25.
Gower
M
, Li
X
, Aguilar-Navarro
AG
, et al. An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup
. Sci Transl Med
. 2025
;17
(779
):eadr2012
.26.
Courtois
L
, Cabannes-Hamy
A
, Kim
R
, et al. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition
. Blood
. 2023
;142
(2
):158
-171
.27.
Ding
YY
, Sussman
JH
, Madden
K
, et al. Targeting senescent stemlike subpopulations in Philadelphia chromosome-like acute lymphoblastic leukemia
. Blood
. 2025
;145
(11
):1195
-1210
.28.
Xu
J
, Chen
C
, Sussman
JH
, et al. A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia
. Nat Cancer
. 2025
;6
:102
-122
.© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2025
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal